硝苯吡啶与牙龈增生关系的临床研究

CLINICAL ASSESSMENT OF THE RELATIONSHIP BETWEEN NIFEDIPINE AND GINGIVAL HYPERPLASIA

目的：探讨服用硝苯吡啶与牙龈增生的关系和诊断标准。方法：对比服用硝苯吡啶（硝苯吡啶组）与不服用者（对照组）的牙龈增生指数、牙石指数、牙龈指数、菌班指数。结果：对照组牙龈增生的患病率为94％，显著高于硝苯吡啶组（77．8％）；硝苯吡啶组中HI＞40％者占13．9％，显著高于对照组（1．45％）。结论：非硝苯吡啶引起的牙龈增生不容忽视，硝苯吡啶确可引起牙龈增生，而与服药持续时间无相关关系；HI＞40％者不难确诊，30％＜HI≤40％者则应结合牙龈状态和病理学结果诊断。

Objective:To ascertain the relationship between nifedipine and gingival hyperplasia. Methods: The gingival hygiene indices between nifedipine administered 72 cases (nifedipine group) and nonnifedipine administered 138 cases (control group) were compared. Hyperplastic index (HI), calculus index (CI), gingival index (GI), plaque index (PLI) were determined and the biopsy of gingival overgrowth was performed. Results:The prevalence of gingival hyperplasia was 94% (130/138) in controlgroup, which was significantly higher than that (77. 8% ) in nifedipine group. The constituent ratio ofHI>40% in nifedipine group was 10/72(13. 9 % ), which was significantly greater than that (2/138) incontrol group (P<0. 001) Conclusion: The incidence of non-nifedipine induced gingival hyperplasia isvery high, but the percentage of nifedipine administered subjects with gingival hyperplasia is greaterthan that of the control (P<0. 001). No statistically significant difference was found between administration duration of nifedipine and the degree of hyperplasia. The diagnosis of nifedipine-induced gingivalhyperplasia may be confirmed when HI>40%. Gingival hygiene indices and biopsy are needed for theverification of borderline cases when 30%<HI≤40%.